1 – 10 of 30
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Next-generation CD40 agonists for cancer immunotherapy
(
- Contribution to journal › Scientific review
- 2023
-
Mark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
(
- Contribution to journal › Article
- 2022
-
Mark
Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
(
- Contribution to journal › Article
- 2021
-
Mark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
(
- Contribution to journal › Article
-
Mark
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
(
- Contribution to journal › Article
- 2015
-
Mark
Kick-starting the cancer-immunity cycle by targeting CD40
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
(
- Contribution to journal › Article
- 2009
-
Mark
Attovial-based antibody nanoarrays.
(
- Contribution to journal › Article